Healthcare Industry News: computed tomography
News Release - October 11, 2007
Integra LifeSciences Partners With TomoTherapy to Deliver Image-Guided Stereotactic RadiosurgeryPLAINSBORO, N.J., Oct. 11, 2007 (Healthcare Sales & Marketing Network) -- Integra LifeSciences Holdings Corporation (NasdaqGS:IART ) announced today that its subsidiary, Integra Radionics, Inc., has entered into a strategic alliance with TomoTherapy Incorporated (NasdaqGM:TTPY ). The companies will develop and supply the InterFix(TM) radiosurgery kit, a collection of stereotactic radiosurgery components for the TomoTherapy(R) Hi-Art(R) system. The Hi-Art(R) treatment system is an advanced radiation delivery system for the treatment of cancer and combines integrated computed tomography (CT) imaging with sophisticated conformal control of target volume irradiation.
The new alliance will focus on methods of precise cranial immobilization for radiosurgery with the Hi-Art(R) system. Integra is poised to offer these capabilities through its research and development team, which has delivered the industry-leading Radionics(R) CRW(R) stereotactic neurosurgery and Radionics(R) XKnife(TM) radiosurgery product lines.
Stereotactic radiosurgery is a minimally invasive technique used to deliver a single high dose of radiation to small, well-defined target volumes, while avoiding nearby normal tissue and critical structures. The targeted volumes are primarily brain tumors and vascular malformations.
``We are delighted to be aligned with Integra,'' said Del Coufal, vice president of marketing at TomoTherapy. ``The addition of Radionics InterFix(TM) radiosurgery kits enhances the radiosurgical solution we can offer TomoTherapy customers worldwide.''
``TomoTherapy has developed a unique radiation treatment system,'' said Christopher von Jako, general manager of Integra Radionics. ``As pioneers and innovators in proven stereotactic neurosurgical and radiosurgical solutions, we are excited about the opportunity this alliance allows for us to expand our radiosurgery offering.''
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. The company's products are used to treat millions of patients every year, primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, Integra's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. For more information visit http://www.Integra-LS.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the TomoTherapy(R) Hi-Art(R) system, InterFix(TM) radiosurgery kit, Radionics(R) CRW(R) stereotactic neurosurgery and Radionics(R) XKnife(TM) radiosurgery product lines, and products developed through the alliance. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the Risk Factors included in Item lA of Integra's Annual Report on Form 10-K for the year ended December 31, 2006, and information contained in subsequent filings with the Securities and Exchange Commission, could affect actual results.
Source: Integra LifeSciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.